After months of delay and suspense, in a Rose Garden ceremony, President Trump and HHS Secretary Alex Azar announced a comprehensive approach to prescription drugs, which they claimed would address major challenges.

The CEO of Ovid Therapeutics, Jeremy Levin, feels no time has ever been better for biopharma leaders to speak out as part of their commitment to this industry.

An in-depth look at J&J’s QuickFire Challenge program and how some of the winners have benefitted (and grown) beyond the cash grants.

Many private biotech companies have either initiated the process of going public or are at least contemplating it. But they should be aware of very significant pitfalls that lie in wait, regardless of how they approach the offering.

Results of a survey asking interviewees about their preferred category of CMO for a certain type of outsourced manufacturing work — full-service CDMOs with end-to-end capabilities or specialty contract manufacturers with expertise in particular areas of need.